Compositions and methods for the treatment of neurodamage
AssigneePrince Biotech, LLC
InventorEytan R. Barnea
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a pharmaceutical composition comprising any one or combination of PIF peptides or analogs or pharmaceutically acceptable salts thereof. Methods of treating cellular neurodamage or neurotrauma to the peripheral or central nervous system using the one or a combination of PIF peptide or analogs thereof or pharmaceutically acceptable salts thereof is also disclosed.
Claims21
A method of improving the clinical outcome in a subject suffering with, diagnosed with or suspected of having peripheral or CNS neurotrauma comprising administering to the subject a pharmaceutical composition comprising:
- (i) a therapeutically effective amount of preimplantation factor (PIF) peptide, an analog thereof, or a pharmaceutically acceptable salt thereof;
- and (ii) a pharmaceutically acceptable carrier.
A method of treating inflammation modulated paralysis in a subject in need thereof comprising administering to the subject at least one pharmaceutical composition comprising:
- (i) a therapeutically effective amount of PIF peptide, an analog thereof, or a pharmaceutically acceptable salt thereof;
- and (ii) a pharmaceutically acceptable carrier.
A method of treating or preventing traumatic injury of the central nervous system in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
- (i) a therapeutically effective amount of PIF peptide, an analog thereof, or a pharmaceutically acceptable salt thereof;
- and (ii) a pharmaceutically acceptable carrier.
A method of treating or preventing peripheral nerve injury in a subject in need thereof, the method comprising administering to the subject at least one pharmaceutical composition comprising:
- (i) a therapeutically effective amount of a PIF peptide, an analog thereof, or a pharmaceutically acceptable salt thereof;
- and (ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.